MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction

Applied Radiology

Volumn 38, Issue 4, 2009, Pages 22-33

  Kuo, Phillip H ^a,g   Abu Alfa, Ali ^c   Bucala, Richard ^d   Griffith, Jason ^b   Carlson, Kacie ^e   Girardi, Michael ^e   Weinreb, Jeffrey ^e   Cowper, Shawn ^f  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Section of Nephrology   (Turkey)

^d Section of Rheumatology

^e Department of Dermatology ^*

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHOVIST; ERYTHROPOIETIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; PENTETIC ACID;

CLINICAL FEATURE; DISEASE COURSE; DRUG MEGADOSE; HEALTH PRACTITIONER; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK REDUCTION;

EID: 65249160161     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356: 1000-1001.
2. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383-393.
3. Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol. 2003;15: 785-790.
4. Cowper S. Nephrogenic Fibrosing Dermopathy Website. In, 2001-2007. Available at http://www. pathmax.com/dermweb/.
5. Fibrosing skin condition among patients with renal disease-United States and Europe 1997- 2002. MMWR. 2002;25-26
6. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: An emerging threat among renal patients. Semin Dial. 2006;19:191-194.
7. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: Suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358.
8. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903-906.
9. Swartz RD, Crofford LJ, Phan SH, et al. Nephrogenic fibrosing dermopathy: A novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563-572.
10. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104-1108.
11. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? [erratum appears in Nephrol Dial Transplant. 2006;21(6):1745]. Nephrol Dial Transplant. 2006; 21(4):1104-1108.
12. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrastenhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
13. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2: 264-267.
14. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: Center case review. J Magn Reson Imaging. 2007;26:1198- 1203.
15. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
16. Kanal E, Broome DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology. 2008; 246:11-14.
17. Jan F, Segal JM, Dyer J, et al. Nephrogenic fibrosing dermopathy: Two pediatric cases. J Pediatr. 2003;143:678-681.
18. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004;19:467-470.
19. Dawn G, Holmes SC. Scleromyxoedema-like eruption following haemodialysis or nephrogenic fibrosing dermopathy? Br J Dermatol. 2004;150: 167-168.
20. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: A novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant. 2004;19:469-473.
21. Tan AW, Tan SH, Lian TY, Ng SK. A case of nephrogenic fibrosing dermopathy. Ann Acad Med Singapore. 2004;33:527-529.
22. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol. 2003;25: 204-209.
23. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema- like illness of renal disease). J Am Acad Dermatol. 2003;48:55-60.
24. Hubbard V, Davenport A, Jarmulowicz M, Rustin M. Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol. 2003; 148:563-568.
25. Edsall LC, English JC, 3rd, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. [erratum appears in J Cutan Pathol. 2004;(7):518]. J Cutan Pathol. 2004;31:247-253.
26. Obermoser G, Emberger M, Wieser M, Zelger B. Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus. 2004;13:609-612.
27. Quan TE, Cowper S, Wu S-P, et al. Circulating fibrocytes: Collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36: 598-606.
28. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: A report of two cases. J Am Acad Dermatol. 2003;48:42-47.
29. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology. 2007;243: 148-157.
30. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006; 145:234-235.
31. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139: 928-930.
32. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30.
33. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26.
34. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007; 242:647-649.
35. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: Relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143:1025-1030.
36. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006;8:145-150.
37. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis- associated systemic fibrosis (nephrogenic fibrosing dermopathy): Study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50: 2660-2666.
38. Mehrad B, Burdick MD, Zisman DA, et al. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun. 2007;353:104-108.
39. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol. 2003;171:380-389.
40. Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen- presenting cell capable of priming naïve T cells in situ. Proc Natl Acad Sci USA. 1997;94: 6307-6312.
41. Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol. 1998;160:419-425.
42. Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol. 2006;45: 429-438.
43. Bucala R. Circulating fibrocytes: Cellular basis for NSF. J Am Coll Radiol. 2008;5:36-39
44. Medicines and Healthcare Products Regulatory Agency (MHRA). Nephrogenic systemic fibrosis (NSF) with gadolinium-containing magnetic resonance imaging (MRI) contrast agents- Update. June 26, 2007. Available at http://www. mhra.gov.uk/Safetyinformation/index.htm
45. Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis. 2005; 46:242-252.
46. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008; 248: 807-816.
47. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
48. Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: Possible association with a predisposing infection. AJR Am J Roentgenol. 2008;190: 1069-1075.
49. Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol. 2008;214:584-593.
50. Kuo PH. Gadolinium-containing MRI contrast agents: Important variations on a theme for NSF. J Am Coll Radiol. 2008; 5:29-35.
51. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media. Invest Radiol. 2008;43:65-75.
52. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: A review. FundamClinPharmacol. 2006;20:563-576.
53. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: Safety update. Top Magn Reson Imaging. 2003;14:426-435.
54. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 2008; 5:45-52
55. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491-502.